nContact atrial fibrillation study
This article was originally published in The Gray Sheet
nContact Surgical Inc. gains FDA investigational device exemption to evaluate combined surgical and catheter treatment of longstanding persistent atrial fibrillation. The study will assess nContact's Numeris AF guided coagulation systemwith VisiTrax in combination with St. Jude Medical's Therapy Cool Path ablation catheter. During the procedure, "a cardiac surgeon and an electrophysiologist work as a team to perform a closed-chest epicardial ablation and endocardial catheter-based ablation," nContact explains
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.